ArticleTranslational psychiatry2025
Preclinical evidence for a novel pharmacotherapeutic approach for treating benzodiazepine addiction.
Lais F Berro, Jemma E Cook, Eliseu C Moreira-Junior, Heather L Hembree, Victoria L Comfort, Daniela Rüedi-Bettschen, Donna M Platt, James K Rowlett
Abstract read
In one paragraphArticle in Translational psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Lais F BerroDepartment of Psychiatry & Human Behavior, University of Mississippi Medical Center, 2500 N State Street, Jackson, MS, 39216, USA.
Jemma E CookDepartment of Psychiatry & Human Behavior, University of Mississippi Medical Center, 2500 N State Street, Jackson, MS, 39216, USA.
Eliseu C Moreira-JuniorDepartment of Psychiatry & Human Behavior, University of Mississippi Medical Center, 2500 N State Street, Jackson, MS, 39216, USA.
Heather L HembreeDepartment of Psychiatry & Human Behavior, University of Mississippi Medical Center, 2500 N State Street, Jackson, MS, 39216, USA.
Donna M PlattDepartment of Psychiatry & Human Behavior, University of Mississippi Medical Center, 2500 N State Street, Jackson, MS, 39216, USA.
Funding
ANXIOLYTIC EFFECTS AND ABUSE OF BZ RECEPTOR LIGANDSR01DA011792 · NIDA · UNIVERSITY OF MISSISSIPPI MED CTR · PI ROWLETT, JAMES K · 1998 to 2024
$7.8MTolerance and Physical Dependence after Chronic Benzodiazepine TreatmentR01DA043204 · NIDA · UNIVERSITY OF MISSISSIPPI MED CTR · PI JAMES K ROWLETT · 2017 to 2026
$4.3MGABA-A receptor subtype mechanisms and the abuse-related effects of alcoholR01AA029023 · NIAAA · UNIVERSITY OF MISSISSIPPI MED CTR · PI PLATT, DONNA M · 2020 to 2024
$2.4MShort Sleep Duration as a Predictor of Methamphetamine Intake: Role of Orexin MechanismsR01DA058666 · NIDA · UNIVERSITY OF MISSISSIPPI MED CTR · PI LAIS F BERRO · 2024 to 2026
$2.3MFentanyl use during pregnancy: impact on dam, placenta, and offspring development.R01DA059181 · NIDA · UNIVERSITY OF MISSISSIPPI MED CTR · PI Daniela Rüedi-Bettschen · 2023 to 2026
$2.0MRole of orexin receptors in the abuse- and sleep-related effects of methamphetamineR00DA049886 · NIDA · UNIVERSITY OF MISSISSIPPI MED CTR · PI BERRO, LAIS F · 2022 to 2024
$747kRole of orexin receptors in the abuse- and sleep-related effects of methamphetamineK99DA049886 · NIDA · UNIVERSITY OF MISSISSIPPI MED CTR · PI BERRO, LAIS F · 2020 to 2021
$256kNIAAA NIH HHS R01 AA029023NIDA NIH HHS K99 DA049886NIDA NIH HHS R00 DA049886NIDA NIH HHS R01 DA011792NIDA NIH HHS R01 DA043204NIDA NIH HHS R01 DA058666NIDA NIH HHS R01 DA059181U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (NIAAA) AA029023U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) DA011792U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) DA043204U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) DA049886U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) DA058666
6 · The paper itselfAbstract
Benzodiazepines are an important class of psychiatric medicines used widely for the treatment of anxiety and sleep disorders, but clinical use is limited by their significant liability for addiction and physical dependence. We identified a compound with a promising pharmacological profile for treating benzodiazepine addiction: The imidazotriazine TPA023B, which has no intrinsic efficacy (i.e., is a silent allosteric modulator) at α1-subunit containing GABA
Indexed as
Anti-Anxiety AgentsBenzodiazepinesSubstance-Related DisordersAnimalsDose-Response Relationship, DrugMacaca mulattaMaleMidazolamRatsRats, Sprague-DawleyReceptors, GABA-ASelf AdministrationAnti-Anxiety AgentsBenzodiazepinesMidazolamReceptors, GABA-A
Identifiers
PMID41271639
PMCPMC12789512
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390